Federal judge rejects expansion of association health plans

A federal judge rejected the Trump administration’s efforts to expand access to association health plans March 29, throwing small businesses that rely on those plans into a state of uncertainty, the Washington Post reported.

U.S. District Judge John D. Bates said association health plans, which allow small business owners and sole proprietors to band together and buy insurance at discounted rates, were “clearly an end-run” around Affordable Care Act provisions and violated the ACA. Association health plans have only been in play for around six months, but companies who did take action in that time are unsure of what their insurance situation will look like if those plans become insolvent.

In the past, policyholders have been stuck with medical bills in these cases, according to the Post. The U.S. Government Accountability Office reported that between 2000 and 2002 there were 144 plans that weren’t authorized to sell health insurance but did, resulting in more than $250 million in unpaid medical claims.

Bates backed his ruling with the comment that sole proprietors of eligible businesses could be counted as both employees and employers under association health plans, which negates established definitions under the Employee Retirement Income Security Act of 1974.

Read the full story below:

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.